PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278697ArticlesСтатьиNEUROLOGICAL ASPECTS OF HIV INFECTIONНЕВРОЛОГИЧЕСКИЕ АСПЕКТЫ ВИЧ-ИНФЕКЦИИMikhailovE VMikhaylovEduard VladimirovichМихайловЭдуард Владимирович

Центр по профилактике и борьбе со СПИД городского округа Тольятти

Центр по профилактике и борьбе со СПИД городского округа Тольятти200920101718-19NO18-19 (2010)№18-19 (2010)101323022023Copyright ©; 2010, Bionika MediaCopyright ©; 2010, ООО «Бионика Медиа»2010Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278697

The article is dedicated to the problem of neurocognitive disorders (VAND) in HIV infection that are making major contributions to clinical disease. It is noted that the incidence of VAND reaches 80% and varies depending on the severity of neurological disorders. The risk factors for VAND are presented; role of HIV replication in cerebrospinal fluid (CSF) is discussed. Control of virus replication in the CSF may play an important role both in prevention of VAND and the recovery of drug-resistant mutant viruses. Therefore, in recent years the ability of different antiretroviral drugs to penetrate the blood-brain barrier into the CNS has particular significance. It is emphasized that client-centered approach and optimized antiretroviral therapy with account of penetration of the blood-brain barrier may provide effective treatment of symptoms of CNS involvement and improvement of clinical outcomes.

Рассматривается проблема нейрокогнитивных расстройств (ВАНР) при ВИЧ-инфекции, вносящих серьезных вклад в клиническую картину заболевания. Отмечается, что частота развития ВАНР достигает 80 % и варьируется в зависимости от тяжести неврологических нарушений. Представлены факторы риска развития ВАНР, обсуждается значение репликации ВИЧ в спинномозговой жидкости (СМЖ). Контроль репликации вируса в СМЖ может играть важную роль как в профилактике ВАНР, так и в выделении устойчивых к препаратам мутантных вирусов. Поэтому в последнее время все большее внимание уделяется способности разных антиретровирусных препаратов проникать через гематоэнцефалический барьер в ЦНС. Подчеркивается, что индивидуальный подход к пациенту и оптимизированная схема антиретровирусной терапии с учетом проникновения через гематоэнцефалический барьер может обеспечить эффективное лечение симптомов поражения ЦНС и улучшение клинических исходов.

human immunodeficiency virusHIV replicationneurocognitive disorderscerebrospinal fluidantiretroviral therapyвирус иммунодефицита человекарепликация ВИЧнейрокогнитивные расстройстваспинномозговая жидкостьантиретровирусная терапияBing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001;58:721-28.Pence BW. The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS. J Antimicrob Chemother 2009;63:636-40.Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing? J Gen Intern Med 2003;18:450-60.Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001;285: 1466-74.Ellis RJ, Deutsch R, Heaton RK, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997;54:416-24.Pence BW, Miller WC, Whetten K, et al. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr. 2006;42:298-306.Cohen M, Hoffman RG, Cromwell C, et al. The prevalence of distress in persons with human immunodeficiency virus infection. Psychosomatics 2002;43:10-15.Rosenberg SD, Trumbetta SL, Mueser KT, et al., Determinants of risk behavior for human immunodeficiency virus/acquired immunodeficiency syndrome in people with severe mental illness. Compr Psychiatry 2001;42:263-71.Dixit AR, Crum RM, Prospective study of depression and the risk of heavy alcohol use in women. Am J Psychiatry 2000;157:751-58.Zell SC. Clinical vignette in antiretroviral therapy: jaundice. J Int Assoc Physicians AIDS Care 2003;2:133-39.Palella FJ Jr, Cole SR, Chmiel JS, et al. Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study. Clin Infect Dis 2004;38:903-07.Santos CP, Felipe YX, Braga PE, et al., Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS 2005;19(Suppl. 4):S14-21.Hult B, Chana G, Masliah E, et al. Neurobiology of HIV. Int Rev Psychiatry 2008;20(1):3-13.Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24(9):1243-50.Heaton R, et al. 16th CROI, Montreal 2009, #154.Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-99.Sacktor N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19:1367-74.Ellis R, et al, Nat Rev Neurosci 2007 and Heaton R, et al. 5th IAS, Capetown 2009, #LBPEB05.Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008;24(10):1301-07.Munoz-Moreno J, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Human Retro 2008,24(10):1301-08.Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV+ individuals. The Hawaii Aging with HIV Cohort. Neurology 2004; 63(5):822-27.Valcour VG, Sacktor NC, Paul RH . Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging With HIV cohort. J Acquir Immune Defic Syndr 20061;43(4):405-10.Cherner M, Letendre S, Heaton RK Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005;64(8):1343-47.Letendre et al. J Infect Dis 2007;196:361-70.Laskus T, Radkowski M, Jablonska J, et al. Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood 2004; 103:3854-59.Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-58.Richardson JL, Nowicki M, Danley K, et al. Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women. AIDS. 2005;19:1659-1667.Canestri A, et al. CID. 2010; 50:773-78.Letendre S, et al. 13th CROI, Denver, 2006, Abstract #74.Letendre S, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.Letendre S, et al. 17th CROI, San Francisco, 2010, #172.Tozzi V, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. JAIDS. 2009;52:56-63.De Socio G, et al. CID. 2008; 46:1938.